For­mer Al­ler­gan ex­ec heads to Re­vance as it chal­lenges Botox; Mark Pruzan­s­ki sur­rounds him­self with more team­mates

→ Re­vance feels like it has a com­pet­i­tive ad­van­tage over Ab­b­Vie’s block­buster Botox with on­ly bian­nu­al in­jec­tions of its fresh­ly ap­proved Daxxi­fy, as op­posed to the in­jec­tions every three or four months that Botox re­quires. But you come at the king, you best not miss, and as Daxxi­fy hits the mar­ket, Re­vance has now tapped David Hol­lan­der as CMO. Hol­lan­der was pre­vi­ous­ly the chief R&D of­fi­cer at Aerie Phar­ma­ceu­ti­cals, which was sold to Al­con a cou­ple months ago in a $770 mil­lion deal, and he has fa­mil­iar­i­ty with the Botox de­vel­op­er through his 10 years at Al­ler­gan. From 2011-16, he was Al­ler­gan’s VP, glob­al ther­a­peu­tic area head in clin­i­cal de­vel­op­ment for an­te­ri­or seg­ment and con­sumer eye care. The Nashville biotech is al­so test­ing Dax­i­bot­u­linum­tox­i­nA in pa­tients with cer­vi­cal dys­to­nia, among oth­er con­di­tions.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN